Eluxadoline and Alosetron Interaction

Drug interaction information between Eluxadoline and Alosetron.

Eluxadoline and Alosetron have a documented minor interaction in FDA labeling.

FDA drug labeling documents a minor-severity interaction between Eluxadoline and Alosetron. This page displays the available source-record category and label text. The category is not an individual risk estimate or medication-combination direction.

Drug A

Eluxadoline

Mu-Opioid Receptor Agonist (IBS-D)

Drug B

Alosetron

5-HT3 Antagonist (IBS-D)

How They Interact

Eluxadoline can interfere with how your body breaks down alosetron, leading to higher amounts of alosetron in your bloodstream.

FDA Label Information

Examples: alosetron, anticholinergics, opioids Table 3: Established and Other Potentially Clinically Relevant Interactions Affecting Drugs Co-Administered with VIBERZI OATP1B1 and BCRP Substrate Clinical Impact: VIBERZI may increase the exposure of co-administered OATP1B1 and BCRP substrates.

Eluxadoline Also Interacts With

View all Eluxadoline interactions →

Frequently Asked Questions

What SPL severity band is on file for Eluxadoline + Alosetron?

Compiled FDA labeling labels this pair minor. That is a source-record field, not an individual medication-combination decision.

Which drug in this pair has the larger labeled-interaction portfolio?

Alosetron has 12 labeled pairs on file vs Eluxadoline's 6. In the minor band specifically: Eluxadoline has 2 (also Cyclosporine); Alosetron has 9 (also Estradiol, Hydralazine, Ketoconazole, Theophylline).

What mechanism field is on file for Eluxadoline and Alosetron?

Eluxadoline can interfere with how your body breaks down alosetron, leading to higher amounts of alosetron in your bloodstream.

Alosetron's labeled portfolio outnumbers Eluxadoline

SPL source-record counts only. This page's band is minor · classes on file: Eluxadoline (Mu-Opioid Receptor Agonist (IBS-D)); Alosetron (5-HT3 Antagonist (IBS-D)).

Eluxadoline

0 major · 4 moderate · 2 minor · 6 total

Alosetron

0 major · 3 moderate · 9 minor · 12 total

Sources: FDA Drug Labels (SPL) via openFDA (2026). This is for informational purposes only and is not medical advice. This registry does not provide individual medication-combination directions.